Literature DB >> 21552285

An essential role for TAK1 in the contact hypersensitivity response.

Yan G Zhao1, Yunqi Wang, Weidong Hao, Yisong Y Wan.   

Abstract

Contact hypersensitivity (CHS) is a delayed-type hypersensitivity that can be induced by haptens, such as 2,4-dinitrofluorobenzene (DNFB). Innate and adaptive immunities are both important for the development of CHS. To treat CHS-related diseases, such as allergic contact dermatitis, a disease prevalent in industrialized countries, ways of interfering with improper immune function during CHS responses need to be identified. Transforming growth factor-β-activated kinase-1 (TAK1), a member of mitogen-activated protein kinase kinase kinase family, is important for both innate and adaptive immunities. We thus hypothesized that the CHS response could be inhibited by interfering with TAK1 activity. Using a mouse model in which TAK1 deletion can be locally induced, we observed that TAK deficiency led to an impaired CHS response and was associated with defective T-cell expansion, activation and interferon (IFN)-γ production. In addition, we investigated the effect of deleting TAK1 specifically in dendritic cells (DC) on the CHS response. We found that when TAK1 is deficient in DC, the CHS response was abolished and hapten-elicited T-cell responses were defective. Collectively, this study demonstrates an essential role of TAK1 in the induction of CHS and suggests that targeting TAK1 could be a viable approach to treat CHS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21552285      PMCID: PMC3129409          DOI: 10.1038/cmi.2011.11

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  36 in total

Review 1.  Allergic contact dermatitis.

Authors:  Pierre Saint-Mezard; Aurore Rosieres; Maya Krasteva; Frédéric Berard; Bertrand Dubois; Dominique Kaiserlian; Jean-François Nicolas
Journal:  Eur J Dermatol       Date:  2004 Sep-Oct       Impact factor: 3.328

2.  Inducing and expanding regulatory T cell populations by foreign antigen.

Authors:  Karsten Kretschmer; Irina Apostolou; Daniel Hawiger; Khashayarsha Khazaie; Michel C Nussenzweig; Harald von Boehmer
Journal:  Nat Immunol       Date:  2005-10-23       Impact factor: 25.606

3.  Skin inflammation during contact hypersensitivity is mediated by early recruitment of CD8+ T cytotoxic 1 cells inducing keratinocyte apoptosis.

Authors:  Hitoshi Akiba; Jeanne Kehren; Marie-Thérèse Ducluzeau; Maya Krasteva; Françoise Horand; Dominique Kaiserlian; Fumio Kaneko; Jean-François Nicolas
Journal:  J Immunol       Date:  2002-03-15       Impact factor: 5.422

4.  Simultaneous blockade of NFkappaB, JNK, and p38 MAPK by a kinase-inactive mutant of the protein kinase TAK1 sensitizes cells to apoptosis and affects a distinct spectrum of tumor necrosis factor [corrected] target genes.

Authors:  Axel Thiefes; Sabine Wolter; J Frederic Mushinski; Elke Hoffmann; Oliver Dittrich-Breiholz; Nadine Graue; Anneke Dörrie; Heike Schneider; Dagmar Wirth; Bruno Luckow; Klaus Resch; Michael Kracht
Journal:  J Biol Chem       Date:  2005-04-18       Impact factor: 5.157

5.  Disparate cytotoxic activity of nickel-specific CD8+ and CD4+ T cell subsets against keratinocytes.

Authors:  C Traidl; S Sebastiani; C Albanesi; H F Merk; P Puddu; G Girolomoni; A Cavani
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

6.  TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo.

Authors:  Jae-Hyuck Shim; Changchun Xiao; Amber E Paschal; Shannon T Bailey; Ping Rao; Matthew S Hayden; Ki-Young Lee; Crystal Bussey; Michael Steckel; Nobuyuki Tanaka; Gen Yamada; Shizuo Akira; Kunihiro Matsumoto; Sankar Ghosh
Journal:  Genes Dev       Date:  2005-10-31       Impact factor: 11.361

7.  Innate CD4+CD25+ regulatory T cells are required for oral tolerance and inhibition of CD8+ T cells mediating skin inflammation.

Authors:  Bertrand Dubois; Ludivine Chapat; Anne Goubier; Martine Papiernik; Jean-François Nicolas; Dominique Kaiserlian
Journal:  Blood       Date:  2003-07-10       Impact factor: 22.113

8.  Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis.

Authors:  Deepa R Hammaker; David L Boyle; Martine Chabaud-Riou; Gary S Firestein
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

Review 9.  The role of ubiquitin in NF-kappaB regulatory pathways.

Authors:  Brian Skaug; Xiaomo Jiang; Zhijian J Chen
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

10.  Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow.

Authors:  Miriam Shapiro-Shelef; Kuo-I Lin; David Savitsky; Jerry Liao; Kathryn Calame
Journal:  J Exp Med       Date:  2005-11-28       Impact factor: 14.307

View more
  5 in total

1.  Transforming growth factor beta-activated kinase 1 (TAK1)-dependent checkpoint in the survival of dendritic cells promotes immune homeostasis and function.

Authors:  Yanyan Wang; Gonghua Huang; Peter Vogel; Geoffrey Neale; Boris Reizis; Hongbo Chi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

Review 2.  Genetic dissection of dendritic cell homeostasis and function: lessons from cell type-specific gene ablation.

Authors:  Peer W F Karmaus; Hongbo Chi
Journal:  Cell Mol Life Sci       Date:  2013-12-24       Impact factor: 9.261

3.  TAK1 deficiency in dendritic cells inhibits adaptive immunity in SRBC-immunized C57BL/6 mice.

Authors:  Yao Pan; Zhiming Lei; Xuetao Wei; Weidong Hao
Journal:  FEBS Open Bio       Date:  2016-04-21       Impact factor: 2.693

Review 4.  Post-Translational Modifications of the TAK1-TAB Complex.

Authors:  Yusuke Hirata; Miki Takahashi; Tohru Morishita; Takuya Noguchi; Atsushi Matsuzawa
Journal:  Int J Mol Sci       Date:  2017-01-19       Impact factor: 5.923

Review 5.  TAK1-TABs Complex: A Central Signalosome in Inflammatory Responses.

Authors:  Yan-Ran Xu; Cao-Qi Lei
Journal:  Front Immunol       Date:  2021-01-05       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.